Neurovascular Adverse Effects of Sars-Cov-2 Vaccination
Leonidas Panos,Panagiotis Bargiotas,Georgios Hadjigeorgiou,Georgios Panos
DOI: https://doi.org/10.2147/dddt.s464394
IF: 4.3188
2024-05-30
Drug Design Development and Therapy
Abstract:Leonidas D Panos, 1, 2 Panagiotis Bargiotas, 2 Georgios Hadjigeorgiou, 2 Georgios D Panos 3, 4 1 Department of Neurology, Bern University Hospital « Inselspital », Bern, Switzerland; 2 Department of Neurology, School of Medicine, University of Cyprus, Nicosia, Cyprus; 3 Department of Ophthalmology, Queen's Medical Centre, Nottingham University Hospitals (NUH), Nottingham, U.K; 4 Division of Ophthalmology and Visual Sciences, School of Medicine, University of Nottingham, Nottingham, U.K Correspondence: Leonidas D Panos, Department of Neurology, Bern University Hospital "Inselspital", Freiburgstrasse 16, 3010, Bern, Switzerland, Tel +41 31 632 70 00, Email Georgios D Panos, Department of Ophthalmology, Queen's Medical Centre, NUH, Derby Road, Lenton, Nottingham, NG7, 2UH, UK, Tel +44 115 924 9924, Email The global deployment of SARS-CoV-2 vaccines has been pivotal in curbing the COVID-19 pandemic, reducing morbidity and mortality associated with the virus. While most of these vaccines have demonstrated high efficacy and overall safety, emerging reports have highlighted potential neurovascular adverse effects, albeit uncommon, associated with these vaccinations. This review aims to assess and summarize the current knowledge on the neurovascular complications arising post-SARS-CoV-2 vaccination. We conducted an extensive literature review, focusing on clinical studies and case reports to identify reported neurovascular events, such as ischemic stroke, cerebral sinus venous thrombosis, intracerebral hemorrhage, pituitary apoplexy and primary CNS angiitis Despite the relative rarity of these events, their impact on affected individuals underscores the importance of ongoing surveillance, early detection, and management strategies. We aim to provide healthcare professionals with the latest evidence on neurovascular adverse effects, facilitating informed decision-making in the context of SARS-CoV-2 vaccination programs. Furthermore, we highlight areas requiring further research to understand the pathophysiology of these adverse events better and to develop targeted prevention and treatment strategies. Keywords: neurovascular adverse effects, COVID-19, vaccines, SARS-CoV-2, coronavirus, pandemic, BNT162b2, mRNA-1273, ChAdOx1, NVX-CoV2373 The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has been a defining global health crisis of our time. 1 In response, the development and global deployment of COVID-19 vaccines have been pivotal in combating the spread of the virus. Representing a monumental achievement in the fields of medicine and biotechnology, these vaccines have been developed using various innovative platforms. Messenger RNA (mRNA) vaccines, like BNT162b2 (Comirnaty, Pfizer-BioNTech) and mRNA-1273 (SpikeVax, Moderna Inc.), use mRNA to teach cells to create the spike protein that prompts an immune response. 2 Viral vector vaccines, including ChAdOx1-S/ nCoV-19 (Vaxzevria, Oxford-AstraZeneca), Ad26.COV2.S (Jcovden, Johnson & Johnson/Janssen), and Gam-Covid-Vac (Sputnik V) employ a different virus to deliver genetic material. 2 Additionally, inactivated or protein subunit vaccines, such as PiCoVacc (CoronaVac, Sinovac) and NVX-CoV2373 (Covovax, Novavax) use a version of the virus that has been killed or parts of the virus like the spike protein. 2 The widespread administration of these vaccines has significantly altered the course of the pandemic. They have been instrumental in reducing the rates of infection, severe illness, hospitalisation and mortality. 3–5 This large-scale vaccination effort has not only illuminated their immediate efficacy and safety but also offered insights into their long-term impact on public health. Billions of doses administered globally have helped societies to gradually reopen and have reduced the burden on healthcare system. 6 Furthermore, the adaptability of these vaccines in addressing emerging variants underscores the agility and responsiveness of modern vaccine technology. 7,8 However, as with all medical interventions, COVID-19 vaccinations come with potential side effects. While the majority are mild and transient, such as pain at the injection site, fatigue, headache, muscle pain, chills, fever, and nausea, there has been a focus on understanding the rare but significant adverse events. 9 Serious side effects like anaphylaxis, myocarditis and pericarditis (particularly after mRNA vaccines in younger males), as well as thrombosis with thrombocytopenia syndrome (TTS) associated with viral vector vaccines, though rare, are areas of ongoing research and monitoring. 10–13 Among these concerns are the neurovascular complications linked to these vaccines. These comp -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal